Analysis of risk of bleeding complications after different doses of Aspirin in 192,036 patients enrolled in 31 randomized controlled trials

被引:256
作者
Serebruany, VL [1 ]
Steinhubl, SR
Berger, PB
Malinin, AI
Baggish, JS
Bhatt, DL
Topol, EJ
机构
[1] McNeil Consumer & Specialty Pharmaceut, Ft Washington, PA USA
[2] Univ Kentucky, Lexington, KY USA
[3] HeartDrug Res Labs, Towson, MD USA
[4] Duke Univ, Durham, NC USA
[5] Cleveland Clin, Cleveland, OH 44106 USA
关键词
D O I
10.1016/j.amjcard.2005.01.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We sought to compare the risk of hemorrhage due to the low (< 100 mg), moderate (100 to 200 mg), and high (> 200 mg) doses of aspirin (acetylsalicylic acid [ASA]) in 192,036 patients enrolled in 31 clinical trials. Despite substantial differences in the reporting patterns of bleeding complications, low-dose ASA was associated with the lowest risk, and moderate doses caused a relatively high hemorrhagic event rate, especially with regard to minor, gastrointestinal, and total bleeding, and stroke. These findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of > 100 mg. (c) 2005 by Excerpts Medica Inc.
引用
收藏
页码:1218 / 1222
页数:5
相关论文
共 38 条
[31]   Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial [J].
Steinhubl, SR ;
Berger, PB ;
Mann, JT ;
Fry, ETA ;
DeLago, A ;
Wilmer, C ;
Topol, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (19) :2411-2420
[32]   Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial [J].
Taylor, DW ;
Barnett, HJM ;
Haynes, RB ;
Ferguson, GG ;
Sackett, DL ;
Thorpe, KE ;
Simard, D ;
Silver, FL ;
Hachinski, V ;
Clagett, GP ;
Barnes, R ;
Spence, JD .
LANCET, 1999, 353 (9171) :2179-2184
[33]  
Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X
[34]  
Topol CE, 2000, LANCET, V355, P337
[35]   AN INTERNATIONAL RANDOMIZED TRIAL COMPARING 4 THROMBOLYTIC STRATEGIES FOR ACUTE MYOCARDIAL-INFARCTION [J].
TOPOL, E ;
CALIFF, R ;
VANDEWERF, F ;
ARMSTRONG, PW ;
AYLWARD, P ;
BARBASH, G ;
BATES, E ;
BETRIU, A ;
BOISSEL, JP ;
CHESEBRO, J ;
COL, J ;
DEBONO, D ;
GORE, J ;
GUERCI, A ;
HAMPTON, J ;
HIRSH, J ;
HOLMES, D ;
HORGAN, J ;
KLEIMAN, N ;
MARDER, V ;
MORRIS, D ;
OHMAN, M ;
PFISTERER, M ;
ROSS, A ;
RUTSCH, W ;
SADOWSKI, Z ;
SIMOONS, M ;
VAHANIAN, A ;
WEAVER, WD ;
WHITE, H ;
WILCOX, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (10) :673-682
[36]   Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease [J].
Topol, EJ ;
Easton, D ;
Harrington, RA ;
Amarenco, P ;
Califf, RM ;
Graffagnino, C ;
Davis, S ;
Diener, HC ;
Ferguson, J ;
Fitzgerald, D ;
Granett, J ;
Shuaib, A ;
Koudstaal, PJ ;
Theroux, P ;
Van de Werf, F ;
Sigmon, K ;
Pieper, K ;
Vallee, M ;
Willerson, JT .
CIRCULATION, 2003, 108 (04) :399-406
[37]  
VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801
[38]  
Yusuf S, 2001, NEW ENGL J MED, V345, P494